Cargando…

Detectable Lipidomes and Metabolomes by Different Plasma Exosome Isolation Methods in Healthy Controls and Patients with Advanced Prostate and Lung Cancer

Circulating exosomes in the blood are promising tools for biomarker discovery in cancer. Due to their heterogeneity, different isolation methods may enrich distinct exosome cargos generating different omic profiles. In this study, we evaluated the effects of plasma exosome isolation methods on detec...

Descripción completa

Detalles Bibliográficos
Autores principales: Soupir, Alex C., Tian, Yijun, Stewart, Paul A., Nunez-Lopez, Yury O., Manley, Brandon J., Pellini, Bruna, Bloomer, Amanda M., Zhang, Jingsong, Mo, Qianxing, Marchion, Douglas C., Liu, Min, Koomen, John M., Siegel, Erin M., Wang, Liang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9916336/
https://www.ncbi.nlm.nih.gov/pubmed/36768152
http://dx.doi.org/10.3390/ijms24031830
_version_ 1784886101023916032
author Soupir, Alex C.
Tian, Yijun
Stewart, Paul A.
Nunez-Lopez, Yury O.
Manley, Brandon J.
Pellini, Bruna
Bloomer, Amanda M.
Zhang, Jingsong
Mo, Qianxing
Marchion, Douglas C.
Liu, Min
Koomen, John M.
Siegel, Erin M.
Wang, Liang
author_facet Soupir, Alex C.
Tian, Yijun
Stewart, Paul A.
Nunez-Lopez, Yury O.
Manley, Brandon J.
Pellini, Bruna
Bloomer, Amanda M.
Zhang, Jingsong
Mo, Qianxing
Marchion, Douglas C.
Liu, Min
Koomen, John M.
Siegel, Erin M.
Wang, Liang
author_sort Soupir, Alex C.
collection PubMed
description Circulating exosomes in the blood are promising tools for biomarker discovery in cancer. Due to their heterogeneity, different isolation methods may enrich distinct exosome cargos generating different omic profiles. In this study, we evaluated the effects of plasma exosome isolation methods on detectable multi-omic profiles in patients with non-small cell lung cancer (NSCLC), castration-resistant prostate cancer (CRPC), and healthy controls, and developed an algorithm to quantify exosome enrichment. Plasma exosomes were isolated from CRPC (n = 10), NSCLC (n = 14), and healthy controls (n = 10) using three different methods: size exclusion chromatography (SEC), lectin binding, and T-cell immunoglobulin domain and mucin domain-containing protein 4 (TIM4) binding. Molecular profiles were determined by mass spectrometry of extracted exosome fractions. Enrichment analysis of uniquely detected molecules was performed for each method with MetaboAnalyst. The exosome enrichment index (EEI) scores methods based on top differential molecules between patient groups. The lipidomic analysis detected 949 lipids using exosomes from SEC, followed by 246 from lectin binding and 226 from TIM4 binding. The detectable metabolites showed SEC identifying 191 while lectin binding and TIM4 binding identified 100 and 107, respectively. When comparing uniquely detected molecules, different methods showed preferential enrichment of different sets of molecules with SEC enriching the greatest diversity. Compared to controls, SEC identified 28 lipids showing significant difference in NSCLC, while only 1 metabolite in NSCLC and 5 metabolites in CRPC were considered statistically significant (FDR < 0.1). Neither lectin-binding- nor TIM4-binding-derived exosome lipids or metabolites demonstrated significant differences between patient groups. We observed the highest EEI from SEC in lipids (NSCLC: 871.33) which was also noted in metabolites. These results support that the size exclusion method of exosome extraction implemented by SBI captures more heterogeneous exosome populations. In contrast, lectin-binding and TIM4-binding methods bind surface glycans or phosphatidylserine moieties of the exosomes. Overall, these findings suggest that specific isolation methods select subpopulations which may significantly impact cancer biomarker discovery.
format Online
Article
Text
id pubmed-9916336
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-99163362023-02-11 Detectable Lipidomes and Metabolomes by Different Plasma Exosome Isolation Methods in Healthy Controls and Patients with Advanced Prostate and Lung Cancer Soupir, Alex C. Tian, Yijun Stewart, Paul A. Nunez-Lopez, Yury O. Manley, Brandon J. Pellini, Bruna Bloomer, Amanda M. Zhang, Jingsong Mo, Qianxing Marchion, Douglas C. Liu, Min Koomen, John M. Siegel, Erin M. Wang, Liang Int J Mol Sci Article Circulating exosomes in the blood are promising tools for biomarker discovery in cancer. Due to their heterogeneity, different isolation methods may enrich distinct exosome cargos generating different omic profiles. In this study, we evaluated the effects of plasma exosome isolation methods on detectable multi-omic profiles in patients with non-small cell lung cancer (NSCLC), castration-resistant prostate cancer (CRPC), and healthy controls, and developed an algorithm to quantify exosome enrichment. Plasma exosomes were isolated from CRPC (n = 10), NSCLC (n = 14), and healthy controls (n = 10) using three different methods: size exclusion chromatography (SEC), lectin binding, and T-cell immunoglobulin domain and mucin domain-containing protein 4 (TIM4) binding. Molecular profiles were determined by mass spectrometry of extracted exosome fractions. Enrichment analysis of uniquely detected molecules was performed for each method with MetaboAnalyst. The exosome enrichment index (EEI) scores methods based on top differential molecules between patient groups. The lipidomic analysis detected 949 lipids using exosomes from SEC, followed by 246 from lectin binding and 226 from TIM4 binding. The detectable metabolites showed SEC identifying 191 while lectin binding and TIM4 binding identified 100 and 107, respectively. When comparing uniquely detected molecules, different methods showed preferential enrichment of different sets of molecules with SEC enriching the greatest diversity. Compared to controls, SEC identified 28 lipids showing significant difference in NSCLC, while only 1 metabolite in NSCLC and 5 metabolites in CRPC were considered statistically significant (FDR < 0.1). Neither lectin-binding- nor TIM4-binding-derived exosome lipids or metabolites demonstrated significant differences between patient groups. We observed the highest EEI from SEC in lipids (NSCLC: 871.33) which was also noted in metabolites. These results support that the size exclusion method of exosome extraction implemented by SBI captures more heterogeneous exosome populations. In contrast, lectin-binding and TIM4-binding methods bind surface glycans or phosphatidylserine moieties of the exosomes. Overall, these findings suggest that specific isolation methods select subpopulations which may significantly impact cancer biomarker discovery. MDPI 2023-01-17 /pmc/articles/PMC9916336/ /pubmed/36768152 http://dx.doi.org/10.3390/ijms24031830 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Soupir, Alex C.
Tian, Yijun
Stewart, Paul A.
Nunez-Lopez, Yury O.
Manley, Brandon J.
Pellini, Bruna
Bloomer, Amanda M.
Zhang, Jingsong
Mo, Qianxing
Marchion, Douglas C.
Liu, Min
Koomen, John M.
Siegel, Erin M.
Wang, Liang
Detectable Lipidomes and Metabolomes by Different Plasma Exosome Isolation Methods in Healthy Controls and Patients with Advanced Prostate and Lung Cancer
title Detectable Lipidomes and Metabolomes by Different Plasma Exosome Isolation Methods in Healthy Controls and Patients with Advanced Prostate and Lung Cancer
title_full Detectable Lipidomes and Metabolomes by Different Plasma Exosome Isolation Methods in Healthy Controls and Patients with Advanced Prostate and Lung Cancer
title_fullStr Detectable Lipidomes and Metabolomes by Different Plasma Exosome Isolation Methods in Healthy Controls and Patients with Advanced Prostate and Lung Cancer
title_full_unstemmed Detectable Lipidomes and Metabolomes by Different Plasma Exosome Isolation Methods in Healthy Controls and Patients with Advanced Prostate and Lung Cancer
title_short Detectable Lipidomes and Metabolomes by Different Plasma Exosome Isolation Methods in Healthy Controls and Patients with Advanced Prostate and Lung Cancer
title_sort detectable lipidomes and metabolomes by different plasma exosome isolation methods in healthy controls and patients with advanced prostate and lung cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9916336/
https://www.ncbi.nlm.nih.gov/pubmed/36768152
http://dx.doi.org/10.3390/ijms24031830
work_keys_str_mv AT soupiralexc detectablelipidomesandmetabolomesbydifferentplasmaexosomeisolationmethodsinhealthycontrolsandpatientswithadvancedprostateandlungcancer
AT tianyijun detectablelipidomesandmetabolomesbydifferentplasmaexosomeisolationmethodsinhealthycontrolsandpatientswithadvancedprostateandlungcancer
AT stewartpaula detectablelipidomesandmetabolomesbydifferentplasmaexosomeisolationmethodsinhealthycontrolsandpatientswithadvancedprostateandlungcancer
AT nunezlopezyuryo detectablelipidomesandmetabolomesbydifferentplasmaexosomeisolationmethodsinhealthycontrolsandpatientswithadvancedprostateandlungcancer
AT manleybrandonj detectablelipidomesandmetabolomesbydifferentplasmaexosomeisolationmethodsinhealthycontrolsandpatientswithadvancedprostateandlungcancer
AT pellinibruna detectablelipidomesandmetabolomesbydifferentplasmaexosomeisolationmethodsinhealthycontrolsandpatientswithadvancedprostateandlungcancer
AT bloomeramandam detectablelipidomesandmetabolomesbydifferentplasmaexosomeisolationmethodsinhealthycontrolsandpatientswithadvancedprostateandlungcancer
AT zhangjingsong detectablelipidomesandmetabolomesbydifferentplasmaexosomeisolationmethodsinhealthycontrolsandpatientswithadvancedprostateandlungcancer
AT moqianxing detectablelipidomesandmetabolomesbydifferentplasmaexosomeisolationmethodsinhealthycontrolsandpatientswithadvancedprostateandlungcancer
AT marchiondouglasc detectablelipidomesandmetabolomesbydifferentplasmaexosomeisolationmethodsinhealthycontrolsandpatientswithadvancedprostateandlungcancer
AT liumin detectablelipidomesandmetabolomesbydifferentplasmaexosomeisolationmethodsinhealthycontrolsandpatientswithadvancedprostateandlungcancer
AT koomenjohnm detectablelipidomesandmetabolomesbydifferentplasmaexosomeisolationmethodsinhealthycontrolsandpatientswithadvancedprostateandlungcancer
AT siegelerinm detectablelipidomesandmetabolomesbydifferentplasmaexosomeisolationmethodsinhealthycontrolsandpatientswithadvancedprostateandlungcancer
AT wangliang detectablelipidomesandmetabolomesbydifferentplasmaexosomeisolationmethodsinhealthycontrolsandpatientswithadvancedprostateandlungcancer